ZA200708158B - Use of paliperidone for the treatment of a mental disorder in a psychiatric patient with reduced hepatic function - Google Patents

Use of paliperidone for the treatment of a mental disorder in a psychiatric patient with reduced hepatic function Download PDF

Info

Publication number
ZA200708158B
ZA200708158B ZA200708158A ZA200708158A ZA200708158B ZA 200708158 B ZA200708158 B ZA 200708158B ZA 200708158 A ZA200708158 A ZA 200708158A ZA 200708158 A ZA200708158 A ZA 200708158A ZA 200708158 B ZA200708158 B ZA 200708158B
Authority
ZA
South Africa
Prior art keywords
disorder
induced
psychotic
intoxication
delusions
Prior art date
Application number
ZA200708158A
Other languages
English (en)
Inventor
Boom Sandra
Erdekens Marielle-Henriette
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of ZA200708158B publication Critical patent/ZA200708158B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Psychology (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
ZA200708158A 2006-09-22 2007-09-21 Use of paliperidone for the treatment of a mental disorder in a psychiatric patient with reduced hepatic function ZA200708158B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11/534,623 US20070197591A1 (en) 2005-12-12 2006-09-22 Use of paliperidone for the treatment of a mental disorder in a psychiatric patient with reduced hepatic function

Publications (1)

Publication Number Publication Date
ZA200708158B true ZA200708158B (en) 2009-08-26

Family

ID=38805865

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200708158A ZA200708158B (en) 2006-09-22 2007-09-21 Use of paliperidone for the treatment of a mental disorder in a psychiatric patient with reduced hepatic function

Country Status (11)

Country Link
US (1) US20070197591A1 (pt)
EP (1) EP1902715A3 (pt)
JP (1) JP2008074852A (pt)
CN (1) CN101264084A (pt)
AU (1) AU2007216873A1 (pt)
BR (1) BRPI0703970A2 (pt)
CO (1) CO6080090A1 (pt)
MX (1) MX2007011783A (pt)
RU (1) RU2007135202A (pt)
SG (1) SG141358A1 (pt)
ZA (1) ZA200708158B (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA72189C2 (uk) 1997-11-17 2005-02-15 Янссен Фармацевтика Н.В. Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот
US8579814B2 (en) * 2007-01-05 2013-11-12 Idexx Laboratories, Inc. Method and system for representation of current and historical medical data
CN101932327A (zh) * 2007-12-19 2010-12-29 詹森药业有限公司 与长效注射用帕潘立酮酯相关的给药方案
WO2011042453A1 (en) * 2009-10-06 2011-04-14 Ascendis Pharma As Subcutaneous paliperidone composition
US20130053405A1 (en) * 2009-10-06 2013-02-28 Ulrich Hersel Carrier linked paliperidone prodrugs
KR20120116401A (ko) * 2009-10-30 2012-10-22 얀센 파마슈티카 엔.브이. 장기-작용성의 주사가능한 팔리페리돈 에스테르와 관련된 투약 요법
WO2011114213A1 (en) 2010-03-15 2011-09-22 Inventia Healthcare Private Limited Stabilized prolonged release pharmaceutical composition comprising atypical antipsychotic
US11331313B2 (en) 2017-05-22 2022-05-17 Whitehead Institute For Biomedical Research KCC2 expression enhancing compounds and uses thereof
EP4734999A1 (en) * 2023-06-29 2026-05-06 Janssen Pharmaceutica NV Method of treating depression using seltorexant

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2000786C (en) 1988-11-07 1999-01-26 Janssen Pharmaceutica, Naamloze Vennootschap 3-piperidinyl-1,2-benzisoxazoles
US6342488B1 (en) * 1998-08-18 2002-01-29 Sepracor, Inc. Phosphonorisperidone and sulforisperidone compositions and methods
CA2549638A1 (en) * 2003-12-23 2005-07-14 Pfizer Products Inc. Therapeutic combination for cognition enhancement and psychotic disorders

Also Published As

Publication number Publication date
MX2007011783A (es) 2009-02-19
JP2008074852A (ja) 2008-04-03
BRPI0703970A2 (pt) 2009-05-26
SG141358A1 (en) 2008-04-28
RU2007135202A (ru) 2009-03-27
EP1902715A3 (en) 2008-11-12
EP1902715A2 (en) 2008-03-26
CO6080090A1 (es) 2009-09-30
CN101264084A (zh) 2008-09-17
AU2007216873A1 (en) 2008-04-10
US20070197591A1 (en) 2007-08-23

Similar Documents

Publication Publication Date Title
EP1902715A2 (en) Use of paliperidone for the treatment of psychiatric patients with reduced hepatic function
JP6037615B2 (ja) 肝性脳症を治療する方法
US11690832B2 (en) Treatment of autoimmune diseases with combinations of RXR agonists and thyroid hormones
US10766867B2 (en) Hydantoins that modulate BACE-mediated APP processing
KR20180064373A (ko) 신경퇴행성 질환과 관련된 환각의 예방 및 치료에 유용한 5-ht2a 세로토닌 수용체의 조절자로서의 다이아릴 및 아릴헤테로아릴 우레아 유도체
US11484502B2 (en) Pharmaceutical composition comprising PDE9 inhibitor
WO2014134569A1 (en) Compositions and methods for treating amyotrophic lateral sclerosis in responders
Delnomdedieu et al. In vivo measurement of PDE10A enzyme occupancy by positron emission tomography (PET) following single oral dose administration of PF-02545920 in healthy male subjects
EP3510029B1 (en) Allosteric corticotropin-releasing factor receptor 1 (crfr1) antagonists that decrease p-tau and improve cognition
JP5563833B2 (ja) （Ｒ）−スピロ［１−アザビシクロ［２．２．２］オクタン−３，２’（３’Ｈ）−フロ［２，３−ｂ］ピリジン（ＡＤＺ０３２８）及びアルツハイマー病、ＡＤＨＤ又は認知機能障害の治療におけるその使用
JP2018505899A (ja) ストレス誘発性ｐ−ｔａｕを低下させるトリアゾロピリジン及びトリアゾロピリミジン
KR20110136826A (ko) 신규의 인지기능장해 치료제
HK1116070A (en) Use of paliperidone for the treatment of psychiatric patients with reduced hepatic function
US20210338670A1 (en) Non-invasive pet imaging of cdk4/6 activation in cancer
TW202320791A (zh) 用於降低尿酸水準的化合物
Nandanwar et al. Preclinical safety evaluation of levonadifloxacin, a novel anti‐methicillin‐resistant Staphyloccocus aureus benzoquinolizine fluoroquinolone by intravenous and oral administration
Jorup et al. Transient paradoxical bronchospasm associated with inhalation of the LAMA AZD9164: analysis of two Phase I, randomised, double-blind, placebo-controlled studies
CA2559312A1 (en) Use of paliperidone for the treatment of a mental disorder in a psychiatric patient with reduced hepatic function
RU2824354C2 (ru) Способы лечения синдрома шегрена с применением ингибитора тирозинкиназы брутона
TW200800216A (en) Treatment of psychiatric patients with reduced hepatic function with paliperidone
Sharma et al. Tailoring MAPK Pathways: New Therapeutics Avenues for Managing Alzheimer’s Diseases
HK40082682A (en) Treatment of autoimmune diseases with combinations of rxr agonists and thyroid hormones